… Prespecified Outcomes The primary outcome of DAPA-HF was the composite of worsening
heart failure (HF hospitalization or urgent visit for HF requiring intravenous therapy) or …

… We compared the baseline characteristics of patients in DAPA-HF with a number of recent
randomized controlled trials.18-21 Two of these had broad inclusion criteria and are shown in …

… have been shown to prevent incident HF hospitalization in patients with diabetes (3–5). … HF
in patients with HFrEF in the DAPA-HF (Dapagliflozin And Prevention of Adverse outcomes in …

… of worsening HF (HF hospitalization or urgent HF visit) or … outcomes assessed in the
current study were the occurrence of HF hospitalization or cardiovascular death; worsening HF …

… in improving outcomes, and well tolerated, across the range of SBP included in DAPA-HF. …
As reported in another recent study, 8 we also analysed outcomes in patients according to …

… before DAPA-HF and the rates of those outcomes in DAPA-HF. The prior trials included few
… patients in DAPA-HF were quite distinct and at much higher cardiovascular risk than patients …

… New-onset type 2 diabetes was a prespecified exploratory endpoint in both DAPA-CKD and
DAPA-HF trials and is the focus of this analysis. New-onset type 2 diabetes was identified by …

… Using study-level published data from DAPA-HF and patient-level data from … renal outcomes
in all randomly assigned patients with HFrEF and in relevant subgroups from DAPA-HF and …

… The key finding of the present analyses is that the benefits of dapagliflozin in DAPA-HF
were obtained regardless of the use of background diuretic therapy or dose of diuretic therapy. …

… Excepting atrial fibrillation, similar trends were seen for patients treated with diuretics and …
the overall DAPA-HF population (especially patients treated with diuretics). Patients receiving …